Compare KE & IMMX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | KE | IMMX |
|---|---|---|
| Founded | 1961 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Electrical Products | Medicinal Chemicals and Botanical Products |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 635.4M | 629.3M |
| IPO Year | 2014 | 2021 |
| Metric | KE | IMMX |
|---|---|---|
| Price | $25.17 | $9.97 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 5 |
| Target Price | ★ $28.00 | $19.20 |
| AVG Volume (30 Days) | 174.8K | ★ 1.6M |
| Earning Date | 05-05-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 0.78 | N/A |
| Revenue | ★ $1,486,727,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $4.57 | N/A |
| P/E Ratio | $33.29 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $18.04 | $1.94 |
| 52 Week High | $33.19 | $11.61 |
| Indicator | KE | IMMX |
|---|---|---|
| Relative Strength Index (RSI) | 49.72 | 64.47 |
| Support Level | $23.54 | $7.99 |
| Resistance Level | $26.91 | $10.61 |
| Average True Range (ATR) | 1.23 | 0.70 |
| MACD | 0.02 | 0.20 |
| Stochastic Oscillator | 53.47 | 95.51 |
Kimball Electronics Inc is a contract electronic manufacturing services company. The company is engaged in producing durable electronics for the automotive, medical, industrial, and public safety end markets. The company's engineering, manufacturing, and supply chain services utilize common production and support capabilities. It is also engaged in producing safety-critical electronic assemblies for its automotive customers. Geographically, it has business units located in the United States, China, Mexico, Poland, Romania, and Thailand. The company derives maximum revenue from Mexico.
Immix Biopharma Inc is engaged in the discovery and development of novel cell therapies for hematologic malignancies (blood cancers) and other indications. It is a clinical-stage biopharmaceutical company developing a novel class of Tissue-Specific Therapeutics TM in oncology and inflammation. Its TME Normalization Technology allows drug candidates to circulate in the bloodstream, exit through tumor blood vessels and simultaneously attack all components of the TME. Its product candidates include CAR-T NXC-201 for autoimmune diseases, and IMX-110 for treatment of soft tissue sarcoma.